Pathogenesis in Menstrual Cycle-Linked CNS Disorders

: That 3alpha‐hydroxy‐5alpha/beta‐pregnane steroids (GABA steroids) have modulatory effects on the GABA‐A receptor is well known. In behavioral studies in animals high exogenous dosages give concentrations not usually reached in the brain under physiological conditions. Animal and human studies show...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences Vol. 1007; no. 1; pp. 42 - 53
Main Authors: BÄCKSTRÖM, TORBJÖRN, ANDERSSON, AGNETA, ANDREÉ, LOTTA, BIRZNIECE, VITA, BIXO, MARIE, BJÖRN, INGER, HAAGE, DAVID, ISAKSSON, MONICA, JOHANSSON, INGA-MAJ, LINDBLAD, CHARLOTT, LUNDGREN, PER, NYBERG, SIGRID, ÖDMARK, INGA-STINA, STRÖMBERG, JESSICA, SUNDSTRÖM-POROMAA, INGER, TURKMEN, SAHRUH, WAHLSTRÖM, GÖRAN, WANG, MINGDE, WIHLBÄCK, ANNA-CARIN, ZHU, DI, ZINGMARK, ELISABETH
Format: Journal Article
Language:English
Published: Oxford, UK Blackwell Publishing Ltd 01-12-2003
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract : That 3alpha‐hydroxy‐5alpha/beta‐pregnane steroids (GABA steroids) have modulatory effects on the GABA‐A receptor is well known. In behavioral studies in animals high exogenous dosages give concentrations not usually reached in the brain under physiological conditions. Animal and human studies show that GABA‐A receptor‐positive modulators like barbiturates, benzodiazepines, alcohol, and allopregnanolone have a bimodal effect. In pharmacological concentrations they are CNS depressants, anesthetic, antiepileptic, and anxiolytic. In low dosages and concentrations, reached endogenously, they can induce adverse emotional reactions in up to 20% of individuals. GABA steroids can also induce tolerance to themselves and similar substances, and rebound occurs at withdrawal. Menstrual cycle‐linked disorders can be understood by the concept that they are caused by the action of endogenously produced GABA‐steroids through three mechanisms: (a) direct action, (b) tolerance induction, and (c) withdrawal effect. Examples of symptoms and disorders caused by the direct action of GABA steroids are sedation, memory and learning disturbance, clumsiness, increased appetite, worsening of petit mal epilepsy, negative mood as tension, irritability and depression during hormone treatments, and the premenstrual dysphoric disorder (PMDD). A continuous exposure to GABA steroids causes tolerance, and women with PMDD are less sensitive to GABA‐A modulators. A malfunctioning GABA‐A receptor system is related to stress sensitivity, concentration difficulties, loss of impulse control, irritability, anxiety, and depression. An example of withdrawal effect is “catamenial epilepsy,” when seizures increase during menstruation after the withdrawal of GABA steroids. Similar phenomena occur at stress since the adrenals produce GABA steroids during stress.
AbstractList That 3alpha-hydroxy-5alpha/beta-pregnane steroids (GABA steroids) have modulatory effects on the GABA-A receptor is well known. In behavioral studies in animals high exogenous dosages give concentrations not usually reached in the brain under physiological conditions. Animal and human studies show that GABA-A receptor-positive modulators like barbiturates, benzodiazepines, alcohol, and allopregnanolone have a bimodal effect. In pharmacological concentrations they are CNS depressants, anesthetic, antiepileptic, and anxiolytic. In low dosages and concentrations, reached endogenously, they can induce adverse emotional reactions in up to 20% of individuals. GABA steroids can also induce tolerance to themselves and similar substances, and rebound occurs at withdrawal. Menstrual cycle-linked disorders can be understood by the concept that they are caused by the action of endogenously produced GABA-steroids through three mechanisms: (a) direct action, (b) tolerance induction, and (c) withdrawal effect. Examples of symptoms and disorders caused by the direct action of GABA steroids are sedation, memory and learning disturbance, clumsiness, increased appetite, worsening of petit mal epilepsy, negative mood as tension, irritability and depression during hormone treatments, and the premenstrual dysphoric disorder (PMDD). A continuous exposure to GABA steroids causes tolerance, and women with PMDD are less sensitive to GABA-A modulators. A malfunctioning GABA-A receptor system is related to stress sensitivity, concentration difficulties, loss of impulse control, irritability, anxiety, and depression. An example of withdrawal effect is "catamenial epilepsy," when seizures increase during menstruation after the withdrawal of GABA steroids. Similar phenomena occur at stress since the adrenals produce GABA steroids during stress.
A bstract : That 3alpha‐hydroxy‐5alpha/beta‐pregnane steroids (GABA steroids) have modulatory effects on the GABA‐A receptor is well known. In behavioral studies in animals high exogenous dosages give concentrations not usually reached in the brain under physiological conditions. Animal and human studies show that GABA‐A receptor‐positive modulators like barbiturates, benzodiazepines, alcohol, and allopregnanolone have a bimodal effect. In pharmacological concentrations they are CNS depressants, anesthetic, antiepileptic, and anxiolytic. In low dosages and concentrations, reached endogenously, they can induce adverse emotional reactions in up to 20% of individuals. GABA steroids can also induce tolerance to themselves and similar substances, and rebound occurs at withdrawal. Menstrual cycle‐linked disorders can be understood by the concept that they are caused by the action of endogenously produced GABA‐steroids through three mechanisms: (a) direct action, (b) tolerance induction, and (c) withdrawal effect. Examples of symptoms and disorders caused by the direct action of GABA steroids are sedation, memory and learning disturbance, clumsiness, increased appetite, worsening of petit mal epilepsy, negative mood as tension, irritability and depression during hormone treatments, and the premenstrual dysphoric disorder (PMDD). A continuous exposure to GABA steroids causes tolerance, and women with PMDD are less sensitive to GABA‐A modulators. A malfunctioning GABA‐A receptor system is related to stress sensitivity, concentration difficulties, loss of impulse control, irritability, anxiety, and depression. An example of withdrawal effect is “catamenial epilepsy,” when seizures increase during menstruation after the withdrawal of GABA steroids. Similar phenomena occur at stress since the adrenals produce GABA steroids during stress.
: That 3alpha‐hydroxy‐5alpha/beta‐pregnane steroids (GABA steroids) have modulatory effects on the GABA‐A receptor is well known. In behavioral studies in animals high exogenous dosages give concentrations not usually reached in the brain under physiological conditions. Animal and human studies show that GABA‐A receptor‐positive modulators like barbiturates, benzodiazepines, alcohol, and allopregnanolone have a bimodal effect. In pharmacological concentrations they are CNS depressants, anesthetic, antiepileptic, and anxiolytic. In low dosages and concentrations, reached endogenously, they can induce adverse emotional reactions in up to 20% of individuals. GABA steroids can also induce tolerance to themselves and similar substances, and rebound occurs at withdrawal. Menstrual cycle‐linked disorders can be understood by the concept that they are caused by the action of endogenously produced GABA‐steroids through three mechanisms: (a) direct action, (b) tolerance induction, and (c) withdrawal effect. Examples of symptoms and disorders caused by the direct action of GABA steroids are sedation, memory and learning disturbance, clumsiness, increased appetite, worsening of petit mal epilepsy, negative mood as tension, irritability and depression during hormone treatments, and the premenstrual dysphoric disorder (PMDD). A continuous exposure to GABA steroids causes tolerance, and women with PMDD are less sensitive to GABA‐A modulators. A malfunctioning GABA‐A receptor system is related to stress sensitivity, concentration difficulties, loss of impulse control, irritability, anxiety, and depression. An example of withdrawal effect is “catamenial epilepsy,” when seizures increase during menstruation after the withdrawal of GABA steroids. Similar phenomena occur at stress since the adrenals produce GABA steroids during stress.
Author STRÖMBERG, JESSICA
ANDREÉ, LOTTA
WAHLSTRÖM, GÖRAN
NYBERG, SIGRID
JOHANSSON, INGA-MAJ
LUNDGREN, PER
ISAKSSON, MONICA
BÄCKSTRÖM, TORBJÖRN
SUNDSTRÖM-POROMAA, INGER
ZHU, DI
ANDERSSON, AGNETA
ZINGMARK, ELISABETH
TURKMEN, SAHRUH
ÖDMARK, INGA-STINA
WANG, MINGDE
HAAGE, DAVID
WIHLBÄCK, ANNA-CARIN
BIRZNIECE, VITA
BIXO, MARIE
BJÖRN, INGER
LINDBLAD, CHARLOTT
Author_xml – sequence: 1
  givenname: TORBJÖRN
  surname: BÄCKSTRÖM
  fullname: BÄCKSTRÖM, TORBJÖRN
  email: Torbjorn.Backstrom@Obgyn.umu.se
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 2
  givenname: AGNETA
  surname: ANDERSSON
  fullname: ANDERSSON, AGNETA
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 3
  givenname: LOTTA
  surname: ANDREÉ
  fullname: ANDREÉ, LOTTA
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 4
  givenname: VITA
  surname: BIRZNIECE
  fullname: BIRZNIECE, VITA
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 5
  givenname: MARIE
  surname: BIXO
  fullname: BIXO, MARIE
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 6
  givenname: INGER
  surname: BJÖRN
  fullname: BJÖRN, INGER
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 7
  givenname: DAVID
  surname: HAAGE
  fullname: HAAGE, DAVID
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 8
  givenname: MONICA
  surname: ISAKSSON
  fullname: ISAKSSON, MONICA
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 9
  givenname: INGA-MAJ
  surname: JOHANSSON
  fullname: JOHANSSON, INGA-MAJ
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 10
  givenname: CHARLOTT
  surname: LINDBLAD
  fullname: LINDBLAD, CHARLOTT
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 11
  givenname: PER
  surname: LUNDGREN
  fullname: LUNDGREN, PER
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 12
  givenname: SIGRID
  surname: NYBERG
  fullname: NYBERG, SIGRID
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 13
  givenname: INGA-STINA
  surname: ÖDMARK
  fullname: ÖDMARK, INGA-STINA
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 14
  givenname: JESSICA
  surname: STRÖMBERG
  fullname: STRÖMBERG, JESSICA
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 15
  givenname: INGER
  surname: SUNDSTRÖM-POROMAA
  fullname: SUNDSTRÖM-POROMAA, INGER
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 16
  givenname: SAHRUH
  surname: TURKMEN
  fullname: TURKMEN, SAHRUH
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 17
  givenname: GÖRAN
  surname: WAHLSTRÖM
  fullname: WAHLSTRÖM, GÖRAN
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 18
  givenname: MINGDE
  surname: WANG
  fullname: WANG, MINGDE
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 19
  givenname: ANNA-CARIN
  surname: WIHLBÄCK
  fullname: WIHLBÄCK, ANNA-CARIN
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 20
  givenname: DI
  surname: ZHU
  fullname: ZHU, DI
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
– sequence: 21
  givenname: ELISABETH
  surname: ZINGMARK
  fullname: ZINGMARK, ELISABETH
  organization: Umeå Neurosteroid Research Center, Department of Clinical Sciences, Obstetrics and Gynecology, Norrlands University Hospital, SE-901 85 Umeå, Sweden
BackLink https://www.ncbi.nlm.nih.gov/pubmed/14993039$$D View this record in MEDLINE/PubMed
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-16450$$DView record from Swedish Publication Index
BookMark eNqFkM1P2zAYhy3EBKXjvBvKidNS_BW7PlaFdaCum9RtsNMrJ3kDhtTp7EbQ_55UqeDIyZfn97zyc0IOfeORkC-Mjhgz6sJ6b-s4YnysRpRmB2TAtDSpUoIfkgGlWqdjw8UxOYnxkdKOk_qIHDNpjKDCDIj8ZTcPzT16jC4mzic_0MdNaG2dTLdFjenc-Scsk-limVy62IQSQ_xMPlXdWTzdv0Py59vV7-n3dP5zdj2dzNMi44ynVuoi51luRY4iLyRWeWm55llZMVZIQZVVRpZccCtZUeaSlxalqqpqnDFLuRiSr703PuO6zWEd3MqGLTTWwaX7O4Em3EO7aoEpmdEOP-_xdWj-txg3sHKxwLq2Hps2gmaZMKxrMyQXPViEJsaA1ZuZUdh1hb4r7LpC17VbnO3Vbb7C8p3fh-wA0QPPrsbtRz5Y_Jss5e6Dab9ycYMvbysbnkBpoTO4XcxgeauluLkzMBOvBp-WCw
CitedBy_id crossref_primary_10_1007_s10072_011_0532_5
crossref_primary_10_1007_s00213_005_0168_3
crossref_primary_10_1002_hbm_24069
crossref_primary_10_1016_j_physbeh_2008_08_015
crossref_primary_10_3389_fphar_2021_706894
crossref_primary_10_1080_10673220902891836
crossref_primary_10_1016_j_pneurobio_2013_09_003
crossref_primary_10_1007_s10989_014_9418_8
crossref_primary_10_1016_j_yhbeh_2019_104655
crossref_primary_10_1111_j_1365_2265_2007_02744_x
crossref_primary_10_1007_s11064_009_9947_2
crossref_primary_10_1016_j_jad_2014_12_040
crossref_primary_10_3389_fmed_2017_00144
crossref_primary_10_1124_jpet_113_203653
crossref_primary_10_1016_j_tem_2008_07_004
crossref_primary_10_1016_j_ajog_2009_03_016
crossref_primary_10_1210_jc_2005_2785
crossref_primary_10_1016_j_jsbmb_2010_06_003
crossref_primary_10_1371_journal_pone_0119351
crossref_primary_10_1016_j_pharmthera_2007_03_011
crossref_primary_10_1016_j_brainres_2014_11_051
crossref_primary_10_1016_j_yebeh_2008_02_004
crossref_primary_10_1007_s00404_009_1347_y
crossref_primary_10_1371_journal_pone_0030608
crossref_primary_10_1016_j_pbb_2006_06_007
crossref_primary_10_1186_1744_8069_5_2
crossref_primary_10_2217_17455057_3_4_395
crossref_primary_10_4155_fmc_10_178
crossref_primary_10_2174_2211556008666190724113554
crossref_primary_10_1016_j_steroids_2011_07_002
crossref_primary_10_1016_j_yfrne_2020_100873
crossref_primary_10_1007_s00429_016_1197_x
crossref_primary_10_1038_mp_2010_120
crossref_primary_10_1016_j_neuron_2008_06_019
crossref_primary_10_1016_j_pharmthera_2007_03_007
crossref_primary_10_1007_s00737_013_0327_1
crossref_primary_10_1016_j_rbre_2014_12_010
crossref_primary_10_1155_2017_8459287
crossref_primary_10_1111_j_1440_1681_2008_04946_x
crossref_primary_10_1002_brb3_890
crossref_primary_10_1016_j_yfrne_2012_08_005
crossref_primary_10_1002_brb3_1845
crossref_primary_10_1002_jnr_24205
crossref_primary_10_1016_j_psyneuen_2010_08_006
crossref_primary_10_1016_j_brainresrev_2007_05_012
crossref_primary_10_1016_j_nlm_2018_08_016
crossref_primary_10_3390_biom12070868
crossref_primary_10_1016_j_jad_2018_12_133
crossref_primary_10_1007_s11845_020_02275_7
crossref_primary_10_1111_j_1468_2982_2006_01061_x
crossref_primary_10_1517_14656566_8_7_989
crossref_primary_10_3389_fncel_2014_00222
crossref_primary_10_1016_j_psyneuen_2009_07_005
crossref_primary_10_1038_nature05324
crossref_primary_10_1080_09513590701253511
crossref_primary_10_1016_j_jad_2012_02_010
crossref_primary_10_1111_j_1476_5381_2010_01059_x
crossref_primary_10_1111_j_1399_5618_2011_00921_x
crossref_primary_10_1007_s00213_008_1372_8
crossref_primary_10_1016_j_brainres_2007_06_057
crossref_primary_10_1016_j_pscychresns_2014_10_020
crossref_primary_10_1111_bph_12861
crossref_primary_10_1016_j_neuroscience_2005_10_016
crossref_primary_10_1007_s00213_014_3567_5
crossref_primary_10_1016_j_pharmthera_2005_05_009
crossref_primary_10_1016_j_pharmthera_2007_04_011
crossref_primary_10_1016_j_yfrne_2023_101098
crossref_primary_10_1155_2016_7950781
crossref_primary_10_1016_j_jad_2012_06_038
crossref_primary_10_3389_fphar_2016_00403
crossref_primary_10_1097_01_ALC_0000171486_97638_BC
crossref_primary_10_1007_s11920_015_0627_4
crossref_primary_10_1038_nn1469
crossref_primary_10_1016_j_contraception_2012_09_024
crossref_primary_10_1016_j_jbtep_2016_07_002
crossref_primary_10_1111_j_1440_1681_2010_05352_x
crossref_primary_10_1016_j_srhc_2011_07_001
crossref_primary_10_1080_09513590400018223
crossref_primary_10_1097_00012272_200510000_00008
crossref_primary_10_1016_j_neuropharm_2014_09_021
crossref_primary_10_1111_j_1467_789X_2005_00188_x
crossref_primary_10_1159_000530805
crossref_primary_10_1586_erp_09_14
crossref_primary_10_1038_s41598_019_51498_x
crossref_primary_10_1177_2631831818824439
crossref_primary_10_1007_s10608_016_9788_7
crossref_primary_10_1111_jne_12063
crossref_primary_10_1517_14656566_9_3_429
crossref_primary_10_1016_j_brainresrev_2005_11_001
crossref_primary_10_1038_sj_mp_4002030
crossref_primary_10_1016_j_jpag_2006_09_014
crossref_primary_10_1007_s13105_011_0127_x
crossref_primary_10_1016_j_maturitas_2008_10_008
crossref_primary_10_1111_apha_12122
crossref_primary_10_1515_HMBCI_2010_070
crossref_primary_10_4236_psych_2019_107068
crossref_primary_10_1016_j_jad_2013_06_042
crossref_primary_10_1016_j_biopsych_2010_09_029
crossref_primary_10_1007_s12529_016_9564_9
crossref_primary_10_1016_j_rbr_2014_12_009
crossref_primary_10_1016_j_ajog_2009_07_061
Cites_doi 10.1523/JNEUROSCI.20-08-02758.2000
10.1016/0169-328X(96)00087-3
10.1016/S0306-4530(01)00010-5
10.1007/BF02247439
10.2165/00023210-200317050-00003
10.1530/acta.0.1250132
10.1016/1059-1311(92)90012-P
10.1212/WNL.54.8.1691
10.1056/NEJM199801223380401
10.1210/jc.85.10.3840
10.1111/j.1530-0277.1990.tb00462.x
10.1007/0-306-47141-8_9
10.1016/S0140-6736(56)90003-4
10.1523/JNEUROSCI.17-05-01848.1997
10.1300/J094v06n04_02
10.3109/00016348809004191
10.1210/jc.81.3.1076
10.1159/000054307
10.1016/S0014-2999(98)00629-3
10.1073/pnas.95.18.10734
10.1111/j.1600-0773.1987.tb01770.x
10.1080/713602990
10.1097/00004714-200210000-00013
10.1016/0006-8993(90)91792-F
10.1016/S0304-3940(98)00479-0
10.1046/j.1471-4159.2000.0751390.x
10.1016/0165-6147(91)90531-V
10.1016/S0010-9452(13)80139-6
10.1016/0006-8993(84)90299-3
10.1016/S0006-8993(02)02414-9
10.1126/science.2422758
10.1016/S0091-3057(96)00218-3
10.1016/0039-128X(90)90031-6
10.1111/j.1360-0443.1994.tb03743.x
10.1016/S0074-7742(01)46071-5
10.1210/jc.83.6.1988
10.1016/S0006-8993(01)02565-3
10.15288/jsas.1993.s11.170
10.1111/j.1530-0277.1994.tb00928.x
10.1111/j.1600-0404.1976.tb04363.x
10.1111/j.1528-1157.1997.tb01197.x
10.1016/S0091-3057(96)00132-3
10.1016/0306-4530(90)90072-H
10.1111/j.1365-2044.1990.tb14683.x
10.1007/s002130000587
10.1530/eje.0.1480571
10.3109/00016348509155154
10.1016/S0893-133X(97)00086-9
10.1210/endo-70-2-196
10.1067/mje.2002.124572
10.1016/0165-0327(94)90059-0
10.1016/S0306-4530(97)00064-4
10.1073/pnas.95.22.13284
10.1210/jc.2002-020755
10.1007/s002280050606
10.3109/01674828309081250
10.1073/pnas.88.10.4553
10.1016/S0306-4530(96)00035-2
10.1016/S0006-8993(98)00782-3
10.1056/NEJM198411223112104
10.1096/fasebj.6.6.1347506
10.1210/jcem-68-1-125
10.1212/WNL.9.5.352
10.1034/j.1600-0412.2000.079005405.x
10.1111/j.1748-1716.1987.tb08202.x
10.1016/0960-0760(95)00179-4
10.1016/0006-8993(91)90761-J
10.1016/0006-8993(88)90615-4
10.1046/j.1468-2982.1996.1601011.x
10.1212/WNL.38.8.1233
10.1034/j.1600-0412.1999.781011.x
10.1067/mob.2000.107781
10.1038/31948
10.1016/S0006-8993(97)00455-1
10.1016/0091-3057(95)02142-6
10.1016/S0091-3057(00)00299-9
10.1038/npp.1993.70
10.1016/0022-3999(87)90097-3
ContentType Journal Article
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ADTPV
AOWAS
D93
DOI 10.1196/annals.1286.005
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
SwePub
SwePub Articles
SWEPUB Umeå universitet
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
CrossRef
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Sciences (General)
Biology
EISSN 1749-6632
EndPage 53
ExternalDocumentID oai_DiVA_org_umu_16450
10_1196_annals_1286_005
14993039
NYAS42
ark_67375_WNG_SW743JX9_G
Genre article
Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
--Z
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1CY
1OB
1OC
23M
31~
33P
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
692
6J9
702
79B
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHHS
AAMDK
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABLJU
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACIWK
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOJD
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AELAQ
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFSWV
AFZJQ
AHBTC
AHEFC
AHMBA
AI.
AIAGR
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BIYOS
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BSCLL
BY8
C45
CAG
CO8
COF
CS3
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRSTM
EBD
EBS
EJD
EMOBN
ESX
F00
F01
F04
F5P
FEDTE
FZ0
G-S
G.N
GODZA
H.T
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
I-F
IH2
IX1
J0M
K48
L7B
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NHB
O66
O9-
OHT
OIG
OK1
OVD
P2P
P2W
P2X
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RAG
RIWAO
RJQFR
ROL
RX1
S10
SAMSI
SJN
SUPJJ
SV3
TEORI
TUS
UB1
UPT
V8K
VH1
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIK
WOHZO
WQJ
WRC
WUP
WVDHM
WXSBR
X7M
XG1
YBU
YOC
YSK
ZGI
ZKB
ZXP
ZZTAW
~02
~IA
~KM
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAMNL
AAYXX
CITATION
7X8
ADTPV
AOWAS
D93
ID FETCH-LOGICAL-c5212-a47cb25ba3be3bc4efbda2725df11c4306a694d232a41cdb42dae46fff851a023
IEDL.DBID 33P
ISSN 0077-8923
1749-6632
IngestDate Sat Aug 24 00:09:47 EDT 2024
Fri Aug 16 12:02:40 EDT 2024
Fri Nov 22 00:07:56 EST 2024
Sat Sep 28 08:35:49 EDT 2024
Sat Aug 24 00:58:51 EDT 2024
Wed Oct 30 09:47:51 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Receptors
GABA-A/physiology
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5212-a47cb25ba3be3bc4efbda2725df11c4306a694d232a41cdb42dae46fff851a023
Notes istex:AE1A31F3866913A7C81AA531D640CEB1E72A3013
ark:/67375/WNG-SW743JX9-G
ArticleID:NYAS42
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1196/annals.1286.005
PMID 14993039
PQID 71539166
PQPubID 23479
PageCount 12
ParticipantIDs swepub_primary_oai_DiVA_org_umu_16450
proquest_miscellaneous_71539166
crossref_primary_10_1196_annals_1286_005
pubmed_primary_14993039
wiley_primary_10_1196_annals_1286_005_NYAS42
istex_primary_ark_67375_WNG_SW743JX9_G
PublicationCentury 2000
PublicationDate December 2003
PublicationDateYYYYMMDD 2003-12-01
PublicationDate_xml – month: 12
  year: 2003
  text: December 2003
PublicationDecade 2000
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: United States
PublicationTitle Annals of the New York Academy of Sciences
PublicationTitleAlternate Ann N Y Acad Sci
PublicationYear 2003
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References Petursson, H. 1994. The benzodiazepine withdrawal syndrome. Addiction 89: 1455-1459.
Norberg, L. et al. 1987. The anaesthetic potency of 3 alpha-hydroxy-5 alpha-pregnan-20-one and 3 alpha-hydroxy-5 beta-pregnan-20-one determined with an intravenous EEG-threshold method in male rats. Pharmacol. Toxicol. 61: 42-47.
Beauchamp, M.H. et al. 2000 Neurosteroids and reward: allopregnanolone produces a conditioned place aversion in rats. Pharmacol. Biochem. Behav. 67: 29-35.
Björn, I. et al. 2002. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy. Gynecol. Endocrinol. 16: 1-8.
Graham, C.A. & B.B. Sherwin. 1987. The relationship between retrospective premenstrual symptom reporting and present oral contraceptive use. J. Psychosom. Res. 31: 45-53.
Gulinello, M. et al. 2001. Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat. Brain Res. 910: 55-66.
Charette, L. et al. 1990. Alcohol consumption and menstrual distress in women at higher and lower risk for alcoholism. Alcohol Clin. Exp. Res. 14: 152-157.
Muse, K.N. et al. 1984. The premenstrual syndrome: effects of "medical ovariectomy." N. Engl. J. Med. 311: 1345-1349.
Kouri, E.M. & U. Halbreich. 1997. State and trait serotonergic abnormalities in women with dysphoric premenstrual syndromes. Psychopharmacol. Bull. 33: 767-770.
Bäckström, T. et al. 1983 Endocrinological aspects on cyclical mood changes or the premenstrual syndrome. J. Psychosom. Obstet. Gynecol. 2: 8-20
Masia, S.L. et al. 2000. Emotional outbursts and post-traumatic stress disorder during intracarotid amobarbital procedure. Neurology 54: 1691-1693.
Sveinsdottir, H. & T. Bäckström. 2000. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet. Gynecol. Scand. 79: 405-413.
Laidlaw, J. 1956 Catamenial epilepsy. Lancet 271: 1235-1237.
Marshall, F.H. et al. 1997. Development of tolerance in mice to the sedative effects of the neuroactive steroid minaxolone following chronic exposure. Pharmacol. Biochem. Behav. 58: 1-8.
Grant, K.A. et al. 1996. Ethanol-like discriminative stimulus effects of the neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one in female Macaca fascicularis monkeys. Psychopharmacology 124: 340-346.
Bäckström, T. et al. 2003. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs 17: 325-342.
Gasior, M. et al. 1997. Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. J. Pharmacol. Exp. Ther. 282: 543-553.
Tobin, M.B. et al. 1994. Reported alcohol use in women with premenstrual syndrome, Am. J. Psychiatry 151: 1503-1504.
Dhar, V. & B.E. Murphy 1990. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology 15: 489-493.
Yu, R. et al. 1996. Down-regulation of the GABA receptor subunits mRNA levels in mammalian cultured cortical neurons following chronic neurosteroid treatment. Brain Res. Mol. Brain Res. 41: 163-168.
Wang, M. et al. 1996. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: Study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alpha-hydroxy-5alpha-pregnan-20-one. J. Clin. Endocrinol. Metab. 81: 1076-1082.
Bitran, D. et al. 1991. Anxiolytic effects of 3 alpha-hydroxy-5 alpha[beta]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor. Brain Res. 561: 157-161.
Sundström, I. et al. 1997. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 22: 25-38.
Kurthen, M. et al. 1991. Severe negative emotional reactions in intracarotid sodium amytal procedures: further evidence for hemispheric asymmetries Cortex 27: 333-337.
Björn, I. et al. 2000. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am. J. Obstet. Gynecol. 183: 1419-1426.
Hammarbäck, S. et al. 1991. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol. 125: 132-137.
Majewska, M.D. et al. 1986. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232: 1004-1007.
Purdy, R.H. et al. 1990. Radioimmunoassay of 3alpha-hydroxy-5alpha-pregnan-20-one in rat and human plasma. Steroids 55: 290-296.
Sibille, E. et al. 2000. Genetic inactivation of the serotonin 1 α receptor in mice results in downregulation of major GABA-A receptor α subunits: reduction of GABA-A receptor binding, and benzodiazepine-resistant anxiety. J. Neurosci. 20: 2758-2765.
Parks, C.L. et al. 1998. Increased anxiety of mice lacking the serotonin 1 α receptor. Proc. Natl. Acad. Sci. USA 95: 10734-10739.
Bäckström, T. et al. 1986. The human corpus luteum secretes 5alpha-pregnane-3,20-dione. Acta Endocrinol. (Copenh.) 111: 116-121.
Österlund, M.K. et al. 2000. Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERalpha mRNA. J. Clin. Endocrinol. Metab. 85: 3840-3846.
Wenzel, R.R. et al. 2002. Central-nervous side effects of midazolam during transesophageal echocardiography. J. Am. Soc. Echocardiogr. 15: 1297-1300.
Khisti, R.T. et al. 1998. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one induces catalepsy in mice. Neurosci. Lett. 251: 85-88.
Andréen, L. et al. 2003. Progesterone effects during hormone replacement therapy. Eur. J. Endocrinol. 148: 571-577.
Sundström, I. & T. Bäckström. 1998. Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. Psychoneuroendocrinology 23: 73-88.
Freeman, E.W. et al. 2002. Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. J. Clin. Psychopharmacol. 22: 516-520.
Hallbreich, U. et al. 1993. Menstrually related disorders: points of consensus, debate, and disagreement. Neuropsychopharmacology 9: 13-15.
Seippe, I. L. & T. Bäckström. 1998. Luteal phase estradiol relates to symptom severity between patients with premenstrual syndrome. J. Clin. Endocrinol. Metab. 83: 1988-1992.
Sundström, I. et al. 1997. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 17: 370-381.
McLeod, D.R. et al. 1994. Family history of alcoholism in women with generalized anxiety disorder who have premenstrual syndrome: patient reports of premenstrual alcohol consumption and symptoms of anxiety, Alcohol Clin. Exp. Res. 18: 664-670.
Smith, S.S. et al. 1998. GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature 392: 926-930.
Wang, M. et al. 2001. Neuroactive steroids and central nervous system disorders. Int. Rev. Neurobiol. 46: 421-459.
Fish, E.W. et al. 2001. Alcohol, allopregnanolone and aggression in mice. Psychopharmacology (Berl.) 153: 473-483.
Hammarbäck, S. et al. 1989. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J. Clin. Endocrinol. Metab. 68: 125-130.
Sundstrom, I. et al. 1999. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet. Gynecol. Scand. 78: 891-899.
Purdy, R.H. et al. 1991. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc. Natl. Acad. Sci. USA 88: 4553-4557.
Sundström, I. 1998. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 67: 126-138.
Grunewald, R.A. et al. 1992. Exacerbation of typical absence seizures by progesterone. Seizure 1: 137-138.
McEwen, B.S. 1991. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol. Sci. 12: 141-147.
Bäckström, T. et al. 1983. Mood, sexuality, hormones and the menstrual cycle. II. Hormone levels and their relationship to premenstrual syndrome. Psychosom. Med. 45: 503-507.
Herzog, A.G. et al. 1997. Three patterns of catamenial epilepsy. Epilepsia 38: 1082-1088.
Harrison, N.L. & M.A. Simmonds. 1984. Modulation of the GABA receptor complex by a steroid anaesthetic. Brain Res. 323: 287-292.
MacGregor, E.A. 1996. "Menstrual" migraine: towards a definition. Cephalalgia 16: 11-21.
Hammarbäck, S. et al. 1985. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement treatment. Acta Obstet. Gynecol. Scand. 64: 393-397.
Landgren, S. et al. 1987. The effect of progesterone and its metabolites on the interictal epileptiform discharge in the cat's cerebral cortex. Acta Physiol Scand 131: 33-42.
Bixo, M. et al. 1997. Progesterone, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-5alpha-pregnane-20-one in specific regions of the human female brain in different endocrine states. Brain Res. 764: 173-178.
Paul, S.M. & RH. Purdy. 1992. Neuroactive steroids. FASEB J. 6: 2311-2322.
Wooley, D.E. & P.S. Timiras. 1962. The gonad-brain relationship: effects of female sex hormones on electro-shock convulsions in the rat. Endocrinology 70: 196-209.
Bixo, M. et al. 1995. Estradiol and testosterone in specific regions of the human female brain in different endocrine states. J. Steroid Biochem. Mol. Biol. 55: 297-303.
Lee, G.P. et al. 1988. Severe behavioral complications following intracarotid sodium amobarbital injection: implications for hemispheric asymmetry of emotion. Neurology 38: 1233-1236.
Banerjee, P.K. & O.C. Snerd, III. 1998. Neuroactive steroids exacerbate gamma-hydroxybutyric acid-induced absence seizures in rats. Eur. J. Pharmacol. 359: 41-48.
Nyberg, S. et al. 2003. Sensitivity to alcohol among patients with premenstrual dysphoric disorder. Psychoneuroendocrinology. In press.
Mok, W.M. & N.R.
2002; 16
1993; 9
2002; 15
1990; 55
1987; 31
1990; 14
1983; 2
1984; 323
1991; 12
1990; 15
2000; 85
1988; 38
1959; 9
2003; 17
1998; 359
1998; 83
2001; 46
1985; 64
1962; 70
1998; 392
1992; 6
1956; 271
1990; 45
1990; 533
1984; 311
1991; 88
2000; 54
1997; 58
1997; 13
1998; 807
1997; 56
1997; 17
1999; 55
1998; 95
1992; 1
2003; 88
1994; 32
1997; 22
2000; 67
1986; 232
1986; 111
1995; 55
1994; 151
2000; 20
1994; 89
1998; 338
2001; 26
2003
2002; 934
1996; 16
1996; 124
1989; 68
1998; 67
1998; 23
1994; 84
1996; 53
1972; 236
1998; 251
1976; 54
1991; 561
1987; 131
1997; 764
1991; 27
1991; 125
2001; 153
1997; 33
1987; 61
1997; 282
2000; 79
1993; 11
2000; 75
2002; 22
1999; 78
2000; 183
1988; 475
1996; 41
1997; 38
1996; 81
1994; 18
2003; 148
2001; 910
1998; 6
1983; 45
Klaiber E.L. (e_1_2_12_77_2) 1997; 22
e_1_2_12_4_2
e_1_2_12_19_2
e_1_2_12_15_2
e_1_2_12_38_2
e_1_2_12_59_2
e_1_2_12_41_2
e_1_2_12_64_2
e_1_2_12_20_2
e_1_2_12_43_2
e_1_2_12_62_2
e_1_2_12_85_2
e_1_2_12_22_2
e_1_2_12_45_2
e_1_2_12_68_2
e_1_2_12_24_2
e_1_2_12_47_2
e_1_2_12_66_2
e_1_2_12_89_2
Bäckström T. (e_1_2_12_2_2) 1983; 45
e_1_2_12_60_2
e_1_2_12_83_2
e_1_2_12_26_2
e_1_2_12_49_2
e_1_2_12_28_2
e_1_2_12_52_2
e_1_2_12_75_2
e_1_2_12_73_2
e_1_2_12_33_2
e_1_2_12_56_2
e_1_2_12_79_2
e_1_2_12_35_2
e_1_2_12_14_2
Chan A.F. (e_1_2_12_17_2) 1994; 84
e_1_2_12_12_2
e_1_2_12_10_2
e_1_2_12_71_2
e_1_2_12_6_2
e_1_2_12_50_2
Nyberg S. (e_1_2_12_54_2) 2003
e_1_2_12_8_2
e_1_2_12_3_2
e_1_2_12_5_2
e_1_2_12_18_2
e_1_2_12_16_2
e_1_2_12_37_2
e_1_2_12_39_2
Tobin M.B. (e_1_2_12_58_2) 1994; 151
Cullberg J. (e_1_2_12_81_2) 1972; 236
e_1_2_12_40_2
e_1_2_12_65_2
e_1_2_12_86_2
e_1_2_12_21_2
Gasior M. (e_1_2_12_31_2) 1997; 282
e_1_2_12_42_2
e_1_2_12_63_2
e_1_2_12_44_2
e_1_2_12_69_2
e_1_2_12_25_2
e_1_2_12_46_2
e_1_2_12_67_2
e_1_2_12_88_2
e_1_2_12_61_2
e_1_2_12_82_2
e_1_2_12_80_2
Sibille E. (e_1_2_12_87_2) 2000; 20
e_1_2_12_27_2
e_1_2_12_48_2
e_1_2_12_29_2
e_1_2_12_30_2
e_1_2_12_51_2
e_1_2_12_76_2
e_1_2_12_32_2
e_1_2_12_53_2
e_1_2_12_74_2
e_1_2_12_34_2
e_1_2_12_55_2
Kouri E.M. (e_1_2_12_84_2) 1997; 33
e_1_2_12_36_2
e_1_2_12_57_2
e_1_2_12_78_2
e_1_2_12_13_2
Bäckström T. (e_1_2_12_23_2) 1986; 111
e_1_2_12_11_2
e_1_2_12_7_2
e_1_2_12_72_2
e_1_2_12_9_2
e_1_2_12_70_2
References_xml – volume: 45
  start-page: 189
  year: 1990
  end-page: 197
  article-title: Emulsion: a preliminary pharmacokinetic and pharmacodynamic study of a new intravenous anaesthetic agent
  publication-title: Anaesthesia
– volume: 16
  start-page: 11
  year: 1996
  end-page: 21
  article-title: “Menstrual” migraine: towards a definition
  publication-title: Cephalalgia
– volume: 323
  start-page: 287
  year: 1984
  end-page: 292
  article-title: Modulation of the GABA receptor complex by a steroid anaesthetic
  publication-title: Brain Res.
– volume: 38
  start-page: 1082
  year: 1997
  end-page: 1088
  article-title: Three patterns of catamenial epilepsy
  publication-title: Epilepsia
– volume: 910
  start-page: 55
  year: 2001
  end-page: 66
  article-title: Short‐term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat
  publication-title: Brain Res.
– volume: 23
  start-page: 73
  year: 1998
  end-page: 88
  article-title: Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial
  publication-title: Psychoneuroendocrinology
– volume: 131
  start-page: 33
  year: 1987
  end-page: 42
  article-title: The effect of progesterone and its metabolites on the interictal epileptiform discharge in the cat's cerebral cortex
  publication-title: Acta Physiol Scand
– volume: 9
  start-page: 352
  year: 1959
  end-page: 360
  article-title: The role of estrogens in catamenial exacerbation of epilepsy
  publication-title: Neurology
– volume: 16
  start-page: 1
  year: 2002
  end-page: 8
  article-title: The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy
  publication-title: Gynecol. Endocrinol.
– volume: 934
  start-page: 125
  year: 2002
  end-page: 131
  article-title: Allopregnanolone inhibits learning in the Morris water maze
  publication-title: Brain Res.
– volume: 38
  start-page: 1233
  year: 1988
  end-page: 1236
  article-title: Severe behavioral complications following intracarotid sodium amobarbital injection: implications for hemispheric asymmetry of emotion
  publication-title: Neurology
– volume: 15
  start-page: 489
  year: 1990
  end-page: 493
  article-title: Double‐blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS)
  publication-title: Psychoneuroendocrinology
– volume: 33
  start-page: 767
  year: 1997
  end-page: 770
  article-title: State and trait serotonergic abnormalities in women with dysphoric premenstrual syndromes
  publication-title: Psychopharmacol. Bull.
– volume: 14
  start-page: 152
  year: 1990
  end-page: 157
  article-title: Alcohol consumption and menstrual distress in women at higher and lower risk for alcoholism
  publication-title: Alcohol Clin. Exp. Res.
– volume: 75
  start-page: 1390
  year: 2000
  end-page: 1397
  article-title: The human brain has distinct regional expression patterns of estrogen receptor alpha mRNA isoforms derived from alternative promoters
  publication-title: J. Neurochem.
– volume: 79
  start-page: 405
  year: 2000
  end-page: 413
  article-title: Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives
  publication-title: Acta Obstet. Gynecol. Scand.
– volume: 18
  start-page: 664
  year: 1994
  end-page: 670
  article-title: Family history of alcoholism in women with generalized anxiety disorder who have premenstrual syndrome: patient reports of premenstrual alcohol consumption and symptoms of anxiety
  publication-title: Alcohol Clin. Exp. Res.
– volume: 125
  start-page: 132
  year: 1991
  end-page: 137
  article-title: Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome
  publication-title: Acta Endocrinol.
– volume: 58
  start-page: 1
  year: 1997
  end-page: 8
  article-title: Development of tolerance in mice to the sedative effects of the neuroactive steroid minaxolone following chronic exposure
  publication-title: Pharmacol. Biochem. Behav.
– volume: 807
  start-page: 84
  year: 1998
  end-page: 90
  article-title: Progesterone withdrawal I: pro‐convulsant effects
  publication-title: Brain Res.
– volume: 311
  start-page: 1345
  year: 1984
  end-page: 1349
  article-title: The premenstrual syndrome: effects of “medical ovariectomy.”
  publication-title: N. Engl. J. Med.
– volume: 236
  start-page: 1
  issue: Suppl.
  year: 1972
  end-page: 84
  article-title: Mood changes and menstrual symptoms with different gestagen/estrogen combinations: a double blind comparison with placebo
  publication-title: Acta Psychiat. Scand.
– volume: 17
  start-page: 370
  year: 1997
  end-page: 381
  article-title: Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects
  publication-title: Neuropsychopharmacology
– volume: 84
  start-page: 1001
  year: 1994
  end-page: 1005
  article-title: Persistence of premenstrual syndrome during low‐dose administration of the progesterone antagonist RU 486
  publication-title: Obstet. Gynecol.
– year: 2003
  article-title: Sensitivity to alcohol among patients with premenstrual dysphoric disorder
  publication-title: Psychoneuroendocrinology
– volume: 251
  start-page: 85
  year: 1998
  end-page: 88
  article-title: The neurosteroid 3 alpha‐hydroxy‐5 alpha‐pregnan‐20‐one induces catalepsy in mice
  publication-title: Neurosci. Lett.
– volume: 13
  start-page: 139
  year: 1997
  end-page: 171
  article-title: Alcohol, GABAA‐benzodiazepine receptor complex, and aggression
  publication-title: Recent Dev. Alcohol
– volume: 764
  start-page: 173
  year: 1997
  end-page: 178
  article-title: Progesterone, 5alpha‐pregnane‐3,20‐dione and 3alpha‐hydroxy‐5alpha‐pregnane‐20‐one in specific regions of the human female brain in different endocrine states
  publication-title: Brain Res.
– volume: 22
  start-page: 549
  year: 1997
  end-page: 58
  article-title: Relationships of serum estradiol levels
  publication-title: menopausal duration and mood during hormonal replacement therapy. Psychoneuroendocrinology
– volume: 61
  start-page: 42
  year: 1987
  end-page: 47
  article-title: The anaesthetic potency of 3 alpha‐hydroxy‐5 alpha‐pregnan‐20‐one and 3 alpha‐hydroxy‐5 beta‐pregnan‐20‐one determined with an intravenous EEG‐threshold method in male rats
  publication-title: Pharmacol. Toxicol.
– volume: 22
  start-page: 516
  year: 2002
  end-page: 520
  article-title: Allopregnanolone levels and symptom improvement in severe premenstrual syndrome
  publication-title: J. Clin. Psychopharmacol.
– volume: 151
  start-page: 1503
  year: 1994
  end-page: 1504
  article-title: Reported alcohol use in women with premenstrual syndrome, Am
  publication-title: J. Psychiatry
– volume: 81
  start-page: 1076
  year: 1996
  end-page: 1082
  article-title: Relationship between symptom severity and steroid variation in women with premenstrual syndrome: Study on serum pregnenolone, pregnenolone sulfate, 5 alpha‐pregnane‐3,20‐dione and 3 alpha‐hydroxy‐5alpha‐pregnan‐20‐one
  publication-title: J. Clin. Endocrinol. Metab.
– volume: 20
  start-page: 2758
  year: 2000
  end-page: 2765
  article-title: Genetic inactivation of the serotonin 1 α receptor in mice results in downregulation of major GABA‐A receptor α subunits: reduction of GABA‐A receptor binding, and benzodiazepine‐resistant anxiety
  publication-title: J. Neurosci.
– volume: 88
  start-page: 2026
  year: 2003
  end-page: 2030
  article-title: Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy
  publication-title: J. Clin. Endocrinol. Metab.
– volume: 55
  start-page: 125
  year: 1999
  end-page: 130
  article-title: Lack of influence of menstrual cycle and premenstrual syndrome diagnosis on pregnanolone pharmacokinetics
  publication-title: Eur. J. Clin. Pharmacol.
– volume: 55
  start-page: 290
  year: 1990
  end-page: 296
  article-title: Radioimmunoassay of 3alpha‐hydroxy‐5alpha‐pregnan‐20‐one in rat and human plasma
  publication-title: Steroids
– volume: 359
  start-page: 41
  year: 1998
  end-page: 48
  article-title: Neuroactive steroids exacerbate gamma‐hydroxybutyric acid‐induced absence seizures in rats
  publication-title: Eur. J. Pharmacol.
– volume: 46
  start-page: 421
  year: 2001
  end-page: 459
  article-title: Neuroactive steroids and central nervous system disorders
  publication-title: Int. Rev. Neurobiol.
– volume: 31
  start-page: 45
  year: 1987
  end-page: 53
  article-title: The relationship between retrospective premenstrual symptom reporting and present oral contraceptive use
  publication-title: J. Psychosom. Res.
– volume: 17
  start-page: 1848
  year: 1997
  end-page: 1859
  article-title: Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor‐mediated synaptic input: correlation with dendritic spine density
  publication-title: J. Neurosci.
– volume: 111
  start-page: 116
  year: 1986
  end-page: 121
  article-title: The human corpus luteum secretes 5alpha‐pregnane‐3,20‐dione
  publication-title: Acta Endocrinol. (Copenh.)
– volume: 153
  start-page: 473
  year: 2001
  end-page: 483
  article-title: Alcohol, allopregnanolone and aggression in mice
  publication-title: Psychopharmacology (Berl.)
– volume: 17
  start-page: 325
  year: 2003
  end-page: 342
  article-title: The role of hormones and hormonal treatments in premenstrual syndrome
  publication-title: CNS Drugs
– volume: 271
  start-page: 1235
  year: 1956
  end-page: 1237
  article-title: Catamenial epilepsy
  publication-title: Lancet
– volume: 68
  start-page: 125
  year: 1989
  end-page: 130
  article-title: Relationship between symptom severity and hormone changes in women with premenstrual syndrome
  publication-title: J. Clin. Endocrinol. Metab.
– volume: 83
  start-page: 1988
  year: 1998
  end-page: 1992
  article-title: Luteal phase estradiol relates to symptom severity between patients with premenstrual syndrome
  publication-title: J. Clin. Endocrinol. Metab.
– volume: 54
  start-page: 321
  year: 1976
  end-page: 347
  article-title: Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle
  publication-title: Acta Neurol. Scand.
– volume: 89
  start-page: 1455
  year: 1994
  end-page: 1459
  article-title: The benzodiazepine withdrawal syndrome
  publication-title: Addiction
– volume: 32
  start-page: 37
  year: 1994
  end-page: 44
  article-title: Acute tryptophan depletion aggravates premenstrual syndrome
  publication-title: J. Affect. Disord.
– volume: 54
  start-page: 1691
  year: 2000
  end-page: 1693
  article-title: Emotional outbursts and post‐traumatic stress disorder during intracarotid amobarbital procedure
  publication-title: Neurology
– volume: 6
  start-page: 2311
  year: 1992
  end-page: 2322
  article-title: Neuroactive steroids
  publication-title: FASEB J.
– volume: 124
  start-page: 340
  year: 1996
  end-page: 346
  article-title: Ethanol‐like discriminative stimulus effects of the neurosteroid 3 alpha‐hydroxy‐5 alpha‐pregnan‐20‐one in female monkeys
  publication-title: Psychopharmacology
– volume: 85
  start-page: 3840
  year: 2000
  end-page: 3846
  article-title: Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERalpha mRNA
  publication-title: J. Clin. Endocrinol. Metab.
– volume: 561
  start-page: 157
  year: 1991
  end-page: 161
  article-title: Anxiolytic effects of 3 alpha‐hydroxy‐5 alpha[beta]‐pregnan‐20‐one: endogenous metabolites of progesterone that are active at the GABAA receptor
  publication-title: Brain Res.
– volume: 64
  start-page: 393
  year: 1985
  end-page: 397
  article-title: Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen‐progestagen postmenopausal replacement treatment
  publication-title: Acta Obstet. Gynecol. Scand.
– volume: 22
  start-page: 25
  year: 1997
  end-page: 38
  article-title: Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study
  publication-title: Psychoneuroendocrinology
– volume: 12
  start-page: 141
  year: 1991
  end-page: 147
  article-title: Non‐genomic and genomic effects of steroids on neural activity
  publication-title: Trends Pharmacol. Sci.
– volume: 27
  start-page: 333
  year: 1991
  end-page: 337
  article-title: Severe negative emotional reactions in intracarotid sodium amytal procedures: further evidence for hemispheric asymmetries
  publication-title: Cortex
– volume: 41
  start-page: 163
  year: 1996
  end-page: 168
  article-title: Down‐regulation of the GABA receptor subunits mRNA levels in mammalian cultured cortical neurons following chronic neurosteroid treatment
  publication-title: Brain Res. Mol. Brain Res.
– volume: 95
  start-page: 10734
  year: 1998
  end-page: 10739
  article-title: Increased anxiety of mice lacking the serotonin 1 α receptor
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 282
  start-page: 543
  year: 1997
  end-page: 553
  article-title: Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 232
  start-page: 1004
  year: 1986
  end-page: 1007
  article-title: Steroid hormone metabolites are barbiturate‐like modulators of the GABA receptor
  publication-title: Science
– volume: 26
  start-page: 551
  year: 2001
  end-page: 564
  article-title: Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5‐HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment
  publication-title: Psychoneuroendocrinology
– volume: 53
  start-page: 777
  year: 1996
  end-page: 782
  article-title: The hyperphagic effect of 3 alpha‐hydroxylated pregnane steroids in male rats
  publication-title: Pharmacol. Biochem. Behav.
– volume: 11
  start-page: 170
  year: 1993
  end-page: 179
  article-title: Alcohol, benzodiazepine‐GABAa receptor complex and aggression: ethological analysis of individual differences in rodents and primates
  publication-title: J. Stud. Alcohol
– volume: 475
  start-page: 272
  year: 1988
  end-page: 282
  article-title: Locally applied estrogens potentiate glutamate‐evoked excitation of cerebellar Purkinje cells
  publication-title: Brain Res.
– volume: 183
  start-page: 1419
  year: 2000
  end-page: 1426
  article-title: Negative mood changes during hormone replacement therapy: a comparison between two progestogens
  publication-title: Am. J. Obstet. Gynecol.
– volume: 338
  start-page: 209
  year: 1998
  end-page: 216
  article-title: Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome
  publication-title: N. Engl. J. Med.
– volume: 56
  start-page: 261
  year: 1997
  end-page: 264
  article-title: Rewarding effect of the neuroactive steroid 3 alpha‐hydroxy‐5 alpha‐pregnan‐20‐one in mice
  publication-title: Pharmacol. Biochem. Behav.
– volume: 533
  start-page: 42
  year: 1990
  end-page: 45
  article-title: Evidence that 5 alpha‐pregnan‐3 alpha‐ol‐20‐one is the metabolite responsible for progesterone anesthesia
  publication-title: Brain Res.
– volume: 55
  start-page: 297
  year: 1995
  end-page: 303
  article-title: Estradiol and testosterone in specific regions of the human female brain in different endocrine states
  publication-title: J. Steroid Biochem. Mol. Biol.
– volume: 9
  start-page: 13
  year: 1993
  end-page: 15
  article-title: Menstrually related disorders: points of consensus, debate, and disagreement
  publication-title: Neuropsychopharmacology
– volume: 392
  start-page: 926
  year: 1998
  end-page: 930
  article-title: GABA(A) receptor alpha4 subunit suppression prevents withdrawal properties of an endogenous steroid
  publication-title: Nature
– volume: 15
  start-page: 1297
  year: 2002
  end-page: 1300
  article-title: Central‐nervous side effects of midazolam during transesophageal echocardiography
  publication-title: J. Am. Soc. Echocardiogr.
– volume: 2
  start-page: 8
  year: 1983
  end-page: 20
  article-title: Endocrinological aspects on cyclical mood changes or the premenstrual syndrome
  publication-title: J. Psychosom. Obstet. Gynecol.
– volume: 95
  start-page: 13284
  year: 1998
  end-page: 13289
  article-title: Role of brain allopregnanolone in the plasticity of gamma‐aminobutyric acid type A receptor in rat brain during pregnancy and after delivery
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 78
  start-page: 891
  year: 1999
  end-page: 899
  article-title: Treatment of premenstrual syndrome with gonadotropin‐releasing hormone agonist in a low dose regimen
  publication-title: Acta Obstet. Gynecol. Scand.
– volume: 6
  start-page: 5
  year: 1998
  end-page: 22
  article-title: Cyclicity affects pain and other symptoms in female fibromyalgia syndrome patients
  publication-title: J. Muscularskeletal Pain
– volume: 45
  start-page: 503
  year: 1983
  end-page: 507
  article-title: Mood, sexuality, hormones and the menstrual cycle
  publication-title: II. Hormone levels and their relationship to premenstrual syndrome. Psychosom. Med.
– volume: 1
  start-page: 137
  year: 1992
  end-page: 138
  article-title: Exacerbation of typical absence seizures by progesterone
  publication-title: Seizure
– volume: 88
  start-page: 4553
  year: 1991
  end-page: 4557
  article-title: Stress‐induced elevations of gamma‐aminobutyric acid type A receptor‐active steroids in the rat brain
  publication-title: Proc. Natl. Acad. Sci. USA
– volume: 70
  start-page: 196
  year: 1962
  end-page: 209
  article-title: The gonad‐brain relationship: effects of female sex hormones on electro‐shock convulsions in the rat
  publication-title: Endocrinology
– volume: 67
  start-page: 29
  year: 2000
  end-page: 35
  article-title: Neurosteroids and reward: allopregnanolone produces a conditioned place aversion in rats
  publication-title: Pharmacol. Biochem. Behav.
– volume: 67
  start-page: 126
  year: 1998
  end-page: 138
  article-title: Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects
  publication-title: Neuroendocrinology
– volume: 148
  start-page: 571
  year: 2003
  end-page: 577
  article-title: Progesterone effects during hormone replacement therapy
  publication-title: Eur. J. Endocrinol.
– volume: 20
  start-page: 2758
  year: 2000
  ident: e_1_2_12_87_2
  article-title: Genetic inactivation of the serotonin 1 α receptor in mice results in downregulation of major GABA‐A receptor α subunits: reduction of GABA‐A receptor binding, and benzodiazepine‐resistant anxiety
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.20-08-02758.2000
  contributor:
    fullname: Sibille E.
– ident: e_1_2_12_50_2
  doi: 10.1016/0169-328X(96)00087-3
– ident: e_1_2_12_86_2
  doi: 10.1016/S0306-4530(01)00010-5
– ident: e_1_2_12_55_2
  doi: 10.1007/BF02247439
– ident: e_1_2_12_80_2
  doi: 10.2165/00023210-200317050-00003
– ident: e_1_2_12_67_2
  doi: 10.1530/acta.0.1250132
– ident: e_1_2_12_36_2
  doi: 10.1016/1059-1311(92)90012-P
– volume: 111
  start-page: 116
  year: 1986
  ident: e_1_2_12_23_2
  article-title: The human corpus luteum secretes 5alpha‐pregnane‐3,20‐dione
  publication-title: Acta Endocrinol. (Copenh.)
  contributor:
    fullname: Bäckström T.
– ident: e_1_2_12_39_2
  doi: 10.1212/WNL.54.8.1691
– ident: e_1_2_12_75_2
  doi: 10.1056/NEJM199801223380401
– volume: 236
  start-page: 1
  year: 1972
  ident: e_1_2_12_81_2
  article-title: Mood changes and menstrual symptoms with different gestagen/estrogen combinations: a double blind comparison with placebo
  publication-title: Acta Psychiat. Scand.
  contributor:
    fullname: Cullberg J.
– ident: e_1_2_12_9_2
  doi: 10.1210/jc.85.10.3840
– ident: e_1_2_12_56_2
  doi: 10.1111/j.1530-0277.1990.tb00462.x
– ident: e_1_2_12_40_2
  doi: 10.1007/0-306-47141-8_9
– ident: e_1_2_12_4_2
  doi: 10.1016/S0140-6736(56)90003-4
– ident: e_1_2_12_16_2
  doi: 10.1523/JNEUROSCI.17-05-01848.1997
– ident: e_1_2_12_60_2
  doi: 10.1300/J094v06n04_02
– ident: e_1_2_12_68_2
  doi: 10.3109/00016348809004191
– ident: e_1_2_12_21_2
  doi: 10.1210/jc.81.3.1076
– ident: e_1_2_12_27_2
  doi: 10.1159/000054307
– ident: e_1_2_12_35_2
  doi: 10.1016/S0014-2999(98)00629-3
– ident: e_1_2_12_88_2
  doi: 10.1073/pnas.95.18.10734
– ident: e_1_2_12_28_2
  doi: 10.1111/j.1600-0773.1987.tb01770.x
– ident: e_1_2_12_48_2
  doi: 10.1080/713602990
– ident: e_1_2_12_70_2
  doi: 10.1097/00004714-200210000-00013
– ident: e_1_2_12_13_2
  doi: 10.1016/0006-8993(90)91792-F
– ident: e_1_2_12_34_2
  doi: 10.1016/S0304-3940(98)00479-0
– ident: e_1_2_12_8_2
  doi: 10.1046/j.1471-4159.2000.0751390.x
– ident: e_1_2_12_12_2
  doi: 10.1016/0165-6147(91)90531-V
– ident: e_1_2_12_46_2
  doi: 10.1016/S0010-9452(13)80139-6
– volume: 151
  start-page: 1503
  year: 1994
  ident: e_1_2_12_58_2
  article-title: Reported alcohol use in women with premenstrual syndrome, Am
  publication-title: J. Psychiatry
  contributor:
    fullname: Tobin M.B.
– ident: e_1_2_12_10_2
  doi: 10.1016/0006-8993(84)90299-3
– ident: e_1_2_12_32_2
  doi: 10.1016/S0006-8993(02)02414-9
– ident: e_1_2_12_11_2
  doi: 10.1126/science.2422758
– ident: e_1_2_12_37_2
  doi: 10.1016/S0091-3057(96)00218-3
– ident: e_1_2_12_22_2
  doi: 10.1016/0039-128X(90)90031-6
– ident: e_1_2_12_59_2
  doi: 10.1111/j.1360-0443.1994.tb03743.x
– ident: e_1_2_12_66_2
  doi: 10.1016/S0074-7742(01)46071-5
– ident: e_1_2_12_79_2
  doi: 10.1210/jc.83.6.1988
– ident: e_1_2_12_42_2
  doi: 10.1016/S0006-8993(01)02565-3
– ident: e_1_2_12_45_2
  doi: 10.15288/jsas.1993.s11.170
– ident: e_1_2_12_57_2
  doi: 10.1111/j.1530-0277.1994.tb00928.x
– ident: e_1_2_12_5_2
  doi: 10.1111/j.1600-0404.1976.tb04363.x
– ident: e_1_2_12_6_2
  doi: 10.1111/j.1528-1157.1997.tb01197.x
– ident: e_1_2_12_51_2
  doi: 10.1016/S0091-3057(96)00132-3
– ident: e_1_2_12_76_2
  doi: 10.1016/0306-4530(90)90072-H
– ident: e_1_2_12_26_2
  doi: 10.1111/j.1365-2044.1990.tb14683.x
– ident: e_1_2_12_44_2
  doi: 10.1007/s002130000587
– ident: e_1_2_12_49_2
  doi: 10.1530/eje.0.1480571
– ident: e_1_2_12_72_2
  doi: 10.3109/00016348509155154
– ident: e_1_2_12_83_2
  doi: 10.1016/S0893-133X(97)00086-9
– ident: e_1_2_12_14_2
  doi: 10.1210/endo-70-2-196
– volume: 282
  start-page: 543
  year: 1997
  ident: e_1_2_12_31_2
  article-title: Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam
  publication-title: J. Pharmacol. Exp. Ther.
  contributor:
    fullname: Gasior M.
– ident: e_1_2_12_38_2
  doi: 10.1067/mje.2002.124572
– ident: e_1_2_12_85_2
  doi: 10.1016/0165-0327(94)90059-0
– ident: e_1_2_12_89_2
  doi: 10.1016/S0306-4530(97)00064-4
– ident: e_1_2_12_52_2
  doi: 10.1073/pnas.95.22.13284
– ident: e_1_2_12_74_2
  doi: 10.1210/jc.2002-020755
– volume: 22
  start-page: 549
  year: 1997
  ident: e_1_2_12_77_2
  article-title: Relationships of serum estradiol levels
  publication-title: menopausal duration and mood during hormonal replacement therapy. Psychoneuroendocrinology
  contributor:
    fullname: Klaiber E.L.
– ident: e_1_2_12_25_2
  doi: 10.1007/s002280050606
– ident: e_1_2_12_3_2
  doi: 10.3109/01674828309081250
– ident: e_1_2_12_18_2
  doi: 10.1073/pnas.88.10.4553
– volume: 33
  start-page: 767
  year: 1997
  ident: e_1_2_12_84_2
  article-title: State and trait serotonergic abnormalities in women with dysphoric premenstrual syndromes
  publication-title: Psychopharmacol. Bull.
  contributor:
    fullname: Kouri E.M.
– volume: 84
  start-page: 1001
  year: 1994
  ident: e_1_2_12_17_2
  article-title: Persistence of premenstrual syndrome during low‐dose administration of the progesterone antagonist RU 486
  publication-title: Obstet. Gynecol.
  contributor:
    fullname: Chan A.F.
– ident: e_1_2_12_53_2
  doi: 10.1016/S0306-4530(96)00035-2
– ident: e_1_2_12_61_2
  doi: 10.1016/S0006-8993(98)00782-3
– ident: e_1_2_12_69_2
  doi: 10.1056/NEJM198411223112104
– ident: e_1_2_12_24_2
  doi: 10.1096/fasebj.6.6.1347506
– ident: e_1_2_12_78_2
  doi: 10.1210/jcem-68-1-125
– ident: e_1_2_12_63_2
  doi: 10.1212/WNL.9.5.352
– ident: e_1_2_12_41_2
  doi: 10.1034/j.1600-0412.2000.079005405.x
– volume: 45
  start-page: 503
  year: 1983
  ident: e_1_2_12_2_2
  article-title: Mood, sexuality, hormones and the menstrual cycle
  publication-title: II. Hormone levels and their relationship to premenstrual syndrome. Psychosom. Med.
  contributor:
    fullname: Bäckström T.
– ident: e_1_2_12_30_2
  doi: 10.1111/j.1748-1716.1987.tb08202.x
– ident: e_1_2_12_19_2
  doi: 10.1016/0960-0760(95)00179-4
– ident: e_1_2_12_29_2
  doi: 10.1016/0006-8993(91)90761-J
– ident: e_1_2_12_15_2
  doi: 10.1016/0006-8993(88)90615-4
– ident: e_1_2_12_7_2
  doi: 10.1046/j.1468-2982.1996.1601011.x
– ident: e_1_2_12_47_2
  doi: 10.1212/WNL.38.8.1233
– ident: e_1_2_12_71_2
  doi: 10.1034/j.1600-0412.1999.781011.x
– ident: e_1_2_12_73_2
  doi: 10.1067/mob.2000.107781
– ident: e_1_2_12_62_2
  doi: 10.1038/31948
– ident: e_1_2_12_65_2
– ident: e_1_2_12_20_2
  doi: 10.1016/S0006-8993(97)00455-1
– ident: e_1_2_12_33_2
  doi: 10.1016/0091-3057(95)02142-6
– ident: e_1_2_12_43_2
  doi: 10.1016/S0091-3057(00)00299-9
– ident: e_1_2_12_64_2
  doi: 10.1038/npp.1993.70
– ident: e_1_2_12_82_2
  doi: 10.1016/0022-3999(87)90097-3
– year: 2003
  ident: e_1_2_12_54_2
  article-title: Sensitivity to alcohol among patients with premenstrual dysphoric disorder
  publication-title: Psychoneuroendocrinology
  contributor:
    fullname: Nyberg S.
SSID ssj0012847
Score 2.1834857
SecondaryResourceType review_article
Snippet : That 3alpha‐hydroxy‐5alpha/beta‐pregnane steroids (GABA steroids) have modulatory effects on the GABA‐A receptor is well known. In behavioral studies in...
That 3alpha-hydroxy-5alpha/beta-pregnane steroids (GABA steroids) have modulatory effects on the GABA-A receptor is well known. In behavioral studies in...
A bstract : That 3alpha‐hydroxy‐5alpha/beta‐pregnane steroids (GABA steroids) have modulatory effects on the GABA‐A receptor is well known. In behavioral...
SourceID swepub
proquest
crossref
pubmed
wiley
istex
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 42
SubjectTerms Affect - physiology
allopregnanolone
Animals
epilepsy
Female
GABA
Humans
menstrual cycle
Menstrual Cycle - physiology
Mood Disorders - etiology
Mood Disorders - physiopathology
Mood Disorders - psychology
Mood Disorders/etiology/physiopathology/psychology
neurosteroid
Pregnanolone - physiology
premenstrual dysphoric disorder
Premenstrual Syndrome - etiology
Premenstrual Syndrome - physiopathology
Premenstrual Syndrome - psychology
Premenstrual Syndrome/etiology/physiopathology/psychology
progesterone
Receptors, GABA-A - physiology
Title Pathogenesis in Menstrual Cycle-Linked CNS Disorders
URI https://api.istex.fr/ark:/67375/WNG-SW743JX9-G/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1196%2Fannals.1286.005
https://www.ncbi.nlm.nih.gov/pubmed/14993039
https://search.proquest.com/docview/71539166
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-16450
Volume 1007
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bS8MwFD7oRPBFndd67YOKgtU1TVv7OOYNwTGY16eQNOkYYicrA_fmT_A3-ks8SbvKRBDB5yZpe77k5DtJzheAndgjriCx50jsPQ7FQg6nQjkBoR53pc9dodc7Ltth8-Hk9EzL5NRHuTC5PkS54KZHhvHXeoBzUdxCEhXqtgjQEfpXvZ2g08wxVjBJHF6r3EfQztf44hB9MXKZQtwHWzj-Vn9sXprSJn79iXSWiqLjZNbMRudz__Af8zBbUFG7nvedKkyodAGm88sphwtQLYZ9Zu8X2tQHixC0kDH2OtpBdjO7m9rXykjQYjuNIbby8fauo1sl7UazbY-kPbMluD0_u2lcOsXVC06sk3kRrzAWxBfcE8oTMVWJkJyExJeJ68YU4wweRFQiHePUjaWgRHJFgyRJkMFx5AHLUEl7qVoFG_mKG0oXa2M0xmMulPSiGpFJoBISBcSC_ZHh2UuusMFMZBKZbGm0DdO2YWgbC_YMMGU53n_SB9NCn903L1j7HunQ1UPELizYHiHHcLjoPRCeqt4gYyF6eGTEgQUrOaBf78TYD-fzyILdHOHyiVbgPu3e1Vmv32GD5wHDENOvWXBoYP3to1nzsd6mZO1vxddhJj82qA_ObEAFkVSbMJnJwZbp4Z8RZ_58
link.rule.ids 230,315,782,786,887,1408,27933,27934,46064,46488
linkProvider Wiley-Blackwell
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB7xUFUuvFogPEoObUUlAsRxEnJcLY-FQoS0tMDJsmMHrRBZRLQS3PgJ_EZ-CTNONghUqULiHGeSzMvf2J4vAN-zgPmKZYGn0Xs8joM8yZXxIsYD6etQ-orWOzrdOD3f3tklmpymF6bih2gW3CgybL6mAKcF6SrKk5reFi20gQmW9hPCURjnEbojtXEEJ81OAqVfm41jzMaIZmp6HxSx-UbAq5lpnJR89y_Y2XCKvoazdj7am_qIL5mGyRqNuq3KfWZgxBSz8Kn6P-X9LMzUkV-6azU99a8vEJ0gaOxfUo7slW6vcI-NZaFFOe17lPL08EgFrtFuO-26Q3bP8iv82ds9bXe8-u8LXkb9vGiyOFMsVDJQJlAZN7nSksUs1LnvZxxLDRklXCMik9zPtOJMS8OjPM8RxEmEAnMwVvQLswAuQhY_1j7ejQWZzKQyOki2mM4jk7MkYg6sDTUvbiqSDWGLk8Q2TKNuBOlGoG4c-Gkt04yTt1d0Ni0OxVm6L7pniIgOzxOx78Dq0HQCI4a2QWRh-oNSxJjkERRHDsxXFn15JpZ_OKUnDvyoTNxcIRLund7flujfXorB9UBglRluObBu7fq_lxbpRavL2eL7hq_C587p8ZE4Okh_L8FEdYqQztEswxha1azAaKkH36y7PwMdBQKz
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3bTuMwEB1BESteuO0C4ZoHQKxEgDhOQh6rlnKPKnV3C0-WHTtVhUgRUSV44xP4Rr6EsZMGgVZCSDzHmSRzPOMzvpwAbCYecQVJPEdi73EoNnI4FcoJCPW4K33uCj3fcdIJ46vD5pGWyamPzsIU-hDVhJuODJOvdYDfybQI8qhUt0WA9jC_6uUEfxwmKJJxLZ_vee1qIUFnX5OMQ0zGSGZKdR80sf_BwLuBaUL7-OF_rLOSFH3PZs1w1Jr5hg-ZhemSi9r1ovPMwZjK5mGy-Dvl4zzMlXGf2zulOPXvnxC0kTIOejpD9nO7n9mXymjQop3GI1p5eXrW5a2SdiPu2CNtz_wX_G0d_WmcOOW_F5xEn-ZFwMJEEF9wTyhPJFSlQnISEl-mrptQLDR4EFGJfIxTN5GCEskVDdI0RQrHkQgsQC0bZGoJbCQsbihdvBvLMZ5woaQXHRCZBiolUUAs2Bk5nt0VEhvMlCaROS6NvmHaNwx9Y8G2AaZqx-9v9M600Gfd-Jh1usiHzq4idmzBxgg5hvGiF0F4pgbDnIWY4pESBxYsFoC-PROLPxzQIwu2CoSrK1qCu9n_V2eD-x4b3g4Z1pj-gQW7BtbPXprF1_UOJctfa74BP9rNFrs4jc9XYKrYQqg30axCDUFVazCey-G66eyv-d8BWQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pathogenesis+in+Menstrual+Cycle%E2%80%90Linked+CNS+Disorders&rft.jtitle=Annals+of+the+New+York+Academy+of+Sciences&rft.au=B%C3%84CKSTR%C3%96M%2C+TORBJ%C3%96RN&rft.au=ANDERSSON%2C+AGNETA&rft.au=ANDRE%C3%89%2C+LOTTA&rft.au=BIRZNIECE%2C+VITA&rft.date=2003-12-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0077-8923&rft.eissn=1749-6632&rft.volume=1007&rft.issue=1&rft.spage=42&rft.epage=53&rft_id=info:doi/10.1196%2Fannals.1286.005&rft.externalDBID=10.1196%252Fannals.1286.005&rft.externalDocID=NYAS42
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0077-8923&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0077-8923&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0077-8923&client=summon